|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.
|
|
 |
|
Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….
|
|
 |
|
Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……
|
|
 |
|
Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….
|
|
|
|
|
|
|
|
|
Matthias Knarr, PhD, and True Rogers, PhD, review the latest insights behind CR formulations using HPMC excipients and how HPMC substitution specifically can assist formulators in developing cutting-edge CR delivery systems with differentiated performance.
|
|
|
Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.
|
|
|
Nicholas DiFranco, MEM, believes by working alone or alongside other well-established excipients for controlled release such as HPMC, the power of carbomer chemistry can help drug developers to overcome common challenges associated with controlled-release formulations without resorting to more complex techniques.
|
|
|
Carin Siow, PhD, explains how the progress to tackle the root causes of medication mis-use has been frustratingly slow and believes the pharma industry’s secret weapon in the fight against non-compliance are functional excipients.
|
|
|
|
|
|
|
|
|

Evonik’s Health Care business serves as an innovation hub to leading global pharmaceutical, medical device and nutraceutical companies. Our broad, versatile portfolio of functional excipients, technologies and CDMO services for oral and parenteral dosage forms makes us a global leader for advanced drug delivery. We also serve as a global CDMO for small molecule APIs, HPAPIs and intermediates, and supply high-quality, innovative cell culture solutions. Evonik operates a trusted global network of manufacturing sites, laboratories and development centers around the world. We have a track record of providing enabling solutions to more than 1,000 pharmaceutical, med-tech and nutraceutical customers worldwide, including 90% of the world’s top life-science companies. Click here for more.

Click image to see Captisol’s latest video

|
|
|
|
|
|
 |
|
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
|
|
 |
|
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
|
|
|
|
|
|
|
|
 |
|
It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …
|
|
 |
|
By: Jasmine Musakhanian, Senior Scientific Director, Gattefossé
INTRODUCTION
Mono and diglycerides, also known as partial glycerides, are versatile lipid excipients that play a pivotal role in the realization of drug products and nutraceuticals. Some well-known excipients in this category are …
|
|
 |
|
Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug performance.
Our latest whitepaper delves into the impact of POLYOX™ PEO (Polyethylene Oxide) on drug …
|
|
|
|
|
Upcoming eNewsletter Features:
April 2 – Inhalation Delivery
April 9 – Formulation Development
|
|
|
|
|
|
|
|